Gail Maderis
President & CEO
Business Management
Antiva Biosciences
United States of America
Biography
Gail Maderis brings over 20 years of leadership in biopharmaceutical companies to the Antiva team. From 2009 to 2015, Gail led BayBio, the industry organization representing and supporting Northern California’s life science community. From 2003 to 2009, Gail served as President and CEO of Five Prime Therapeutics, Inc., a protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Gail held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Gail also practiced management and strategy consulting with Bain & Co. She currently serves on the boards of NovaBay Pharmaceuticals (NBY) and Opexa Therapeutics (OPXA). She received a BS in business from UC Berkeley and an MBA from Harvard Business School.
Research Interest
Business Management
